Atea Pharmaceuticals Inc. (NASDAQ: AVIR) started the day on May 25, 2023, with a price decrease of -3.74% at $4.63. During the day, the stock rose to $4.82 and sunk to $4.45 before settling in for the price of $4.81 at the close. Taking a more long-term approach, AVIR posted a 52-week range of $2.94-$9.79.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Nevertheless, stock’s Earnings Per Share (EPS) this year is -201.40%. This publicly-traded company’s shares outstanding now amounts to $83.33 million, simultaneously with a float of $75.70 million. The organization now has a market capitalization sitting at $374.66 million. At the time of writing, stock’s 50-day Moving Average stood at $3.47, while the 200-day Moving Average is $4.87.
Atea Pharmaceuticals Inc. (AVIR) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Atea Pharmaceuticals Inc.’s current insider ownership accounts for 0.90%, in contrast to 69.80% institutional ownership. According to the most recent insider trade that took place on Nov 14, this organization’s Director sold 16,166 shares at the rate of 5.16, making the entire transaction reach 83,352 in total value, affecting insider ownership by 778,353. Preceding that transaction, on Nov 11, Company’s Director sold 25,500 for 5.15, making the whole transaction’s value amount to 131,333. This particular insider is now the holder of 794,519 in total.
Atea Pharmaceuticals Inc. (AVIR) Earnings and Revenue Records
In the latest quarterly report released, which was put into the public domain on 3/30/2023, the organization reported -$0.43 earnings per share (EPS) for the three months, surpassing the consensus estimate (set at -$0.48) by $0.05. This company achieved a return on equity of -17.16. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.53 per share during the current fiscal year.
Atea Pharmaceuticals Inc.’s EPS decrease for this current 12-month fiscal period is -201.40% and is forecasted to reach -2.84 in the upcoming year.
Atea Pharmaceuticals Inc. (NASDAQ: AVIR) Trading Performance Indicators
Let’s observe the current performance indicators for Atea Pharmaceuticals Inc. (AVIR). It’s Quick Ratio in the last reported quarter now stands at 51.20. The Stock has managed to achieve an average true range (ATR) of 0.27.
In the same vein, AVIR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.31, a figure that is expected to reach -0.47 in the next quarter, and analysts are predicting that it will be -2.84 at the market close of one year from today.
Technical Analysis of Atea Pharmaceuticals Inc. (AVIR)
If we take a close look at the recent performances of Atea Pharmaceuticals Inc. (NASDAQ: AVIR), its last 5-days Average volume was 2.55 million that shows progress from its year to date volume of 0.62 million. During the previous 9 days, stock’s Stochastic %D was recorded 79.76% While, its Average True Range was 0.31.
Raw Stochastic average of Atea Pharmaceuticals Inc. (AVIR) in the period of the previous 100 days is set at 75.11%, which indicates a major rise in contrast to 72.00% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 139.63% that was higher than 70.53% volatility it exhibited in the past 100-days period.
